[HTML][HTML] Dopamine D2 receptor agonist, bromocriptine, remodels adipose tissue dopaminergic signalling and upregulates catabolic pathways, improving metabolic …
G Tavares, D Marques, C Barra, D Rosendo-Silva… - Molecular …, 2021 - Elsevier
Background and objectives The therapeutic effects of the dopamine D2 receptor (D2R)
agonist, bromocriptine, in type 2 diabetes (T2D) have been attributed to central nervous …
agonist, bromocriptine, in type 2 diabetes (T2D) have been attributed to central nervous …
[PDF][PDF] Dopamine D2 receptor agonist, bromocriptine, remodels adipose tissue dopaminergic signalling and upregulates catabolic pathways, improving metabolic …
G Tavares, D Marques, C Barra, D Rosendo-Silva… - 2021 - novaresearch.unl.pt
Background and objectives: The therapeutic effects of the dopamine D2 receptor (D2R)
agonist, bromocriptine, in type 2 diabetes (T2D) have been attributed to central nervous …
agonist, bromocriptine, in type 2 diabetes (T2D) have been attributed to central nervous …
[PDF][PDF] Dopamine D2 receptor agonist, bromocriptine, remodels adipose tissue dopaminergic signalling and upregulates catabolic pathways, improving metabolic …
G Tavares, D Marques, C Barra, D Rosendo-Silva… - 2021 - nms.unl.pt
Background and objectives: The therapeutic effects of the dopamine D2 receptor (D2R)
agonist, bromocriptine, in type 2 diabetes (T2D) have been attributed to central nervous …
agonist, bromocriptine, in type 2 diabetes (T2D) have been attributed to central nervous …
Dopamine D2 receptor agonist, bromocriptine, remodels adipose tissue dopaminergic signalling and upregulates catabolic pathways, improving metabolic profile in …
G Tavares, D Marques, C Barra, D Rosendo-Silva… - Molecular …, 2021 - baes.uc.pt
The therapeutic effects of the dopamine D2 receptor (D2R) agonist, bromocriptine, in type 2
diabetes (T2D) have been attributed to central nervous system actions. However, peripheral …
diabetes (T2D) have been attributed to central nervous system actions. However, peripheral …
[PDF][PDF] Dopamine D2 receptor agonist, bromocriptine, remodels adipose tissue dopaminergic signalling and upregulates catabolic pathways, improving metabolic …
G Tavares, D Marques, C Barra, D Rosendo-Silva… - 2021 - researchgate.net
Background and objectives: The therapeutic effects of the dopamine D2 receptor (D2R)
agonist, bromocriptine, in type 2 diabetes (T2D) have been attributed to central nervous …
agonist, bromocriptine, in type 2 diabetes (T2D) have been attributed to central nervous …
[PDF][PDF] Dopamine D2 receptor agonist, bromocriptine, remodels adipose tissue dopaminergic signalling and upregulates catabolic pathways, improving metabolic …
G Tavares, D Marques, C Barra, D Rosendo-Silva… - 2021 - academia.edu
Background and objectives: The therapeutic effects of the dopamine D2 receptor (D2R)
agonist, bromocriptine, in type 2 diabetes (T2D) have been attributed to central nervous …
agonist, bromocriptine, in type 2 diabetes (T2D) have been attributed to central nervous …
[PDF][PDF] Dopamine D2 receptor agonist, bromocriptine, remodels adipose tissue dopaminergic signalling and upregulates catabolic pathways, improving metabolic …
G Tavares, D Marques, C Barra, D Rosendo-Silva… - 2021 - run.unl.pt
Background and objectives: The therapeutic effects of the dopamine D2 receptor (D2R)
agonist, bromocriptine, in type 2 diabetes (T2D) have been attributed to central nervous …
agonist, bromocriptine, in type 2 diabetes (T2D) have been attributed to central nervous …
Dopamine D2 receptor agonist, bromocriptine, remodels adipose tissue dopaminergic signalling and upregulates catabolic pathways, improving metabolic profile in …
G Tavares, D Marques, C Barra… - Molecular …, 2021 - estudogeral.uc.pt
The therapeutic effects of the dopamine D2 receptor (D2R) agonist, bromocriptine, in type 2
diabetes (T2D) have been attributed to central nervous system actions. However, peripheral …
diabetes (T2D) have been attributed to central nervous system actions. However, peripheral …
Dopamine D2 receptor agonist, bromocriptine, remodels adipose tissue dopaminergic signalling and upregulates catabolic pathways, improving metabolic profile in …
G Tavares, D Marques, C Barra… - Molecular …, 2021 - europepmc.org
Methods The expression of dopamine receptors was evaluated in visceral AT samples from
patients with obesity and stratified in several groups: insulin sensitive (IS); insulin resistance …
patients with obesity and stratified in several groups: insulin sensitive (IS); insulin resistance …
Dopamine D2 receptor agonist, bromocriptine, remodels adipose tissue dopaminergic signalling and upregulates catabolic pathways, improving metabolic profile in …
G Tavares, D Marques, C Barra… - Molecular …, 2021 - pubmed.ncbi.nlm.nih.gov
Background and objectives The therapeutic effects of the dopamine D2 receptor (D2R)
agonist, bromocriptine, in type 2 diabetes (T2D) have been attributed to central nervous …
agonist, bromocriptine, in type 2 diabetes (T2D) have been attributed to central nervous …